Incapacitating solar urticaria: successful treatment with omalizumab
An. bras. dermatol
;
94(3): 331-333, May-June 2019. graf
Artículo
en Inglés
| LILACS
| ID: biblio-1011115
ABSTRACT
Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Luz Solar
/
Urticaria
/
Antialérgicos
/
Omalizumab
Tipo de estudio:
Estudio diagnóstico
/
Estudio de etiología
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
An. bras. dermatol
Asunto de la revista:
Dermatologia
Año:
2019
Tipo del documento:
Artículo
País de afiliación:
Portugal
Institución/País de afiliación:
Centro Hospitalar de Leiria/PT
Similares
MEDLINE
...
LILACS
LIS